Proteasome inhibitors
The present invention relates to a compound of formula (I), wherein X is C═O, C═S or B—OH; Y is an electrophile and Z is a leaving group, or Y═Z is an electrophile; R 1 comprises or consists of (a) (i) a first group binding to a proteolytic site of a proteasome, the first group being bound to X; and (ii) optionally a second group enhancing delivery; or (b) a group binding between subunits β1 and β2 of a proteasome; R 2 and R 3 are independently selected from H, methyl, methoxy, ethyl, ethenyl, ethynyl and cyano, wherein methyl and ethyl may be substituted with OH or halogen.
1. A compound of formula (I)
wherein
X is C═O, C═S or B—OH;
Y is an electrophile and Z is a leaving group, or Y═Z is an electrophile;
R 1 is a peptidic group, wherein said peptidic group consists of three α-amino acids and wherein
(a) the N-terminal amino acid is selected from Ser(OMe), Leu, Phe and Ala; the middle amino acid is selected from Ser(OMe), Leu, Phe and Ala; and/or the C-terminal amino acid is attached to X and is a truncated amino acid residue that lacks a carbonyl group, wherein the truncated amino acid residue is based upon an amino acid selected from Phe, Tyr, Leu, Ser(OMe) and Ala; or
(b) said peptidic group consists of Ser(OMe)-Ser(OMe)-Phe, Leu-Leu-Tyr or Ala-Ala-Ala
R 2 and R 3 are independently selected from H, methyl, methoxy, ethyl, ethenyl, ethynyl and cyano, wherein methyl and ethyl may be substituted with OH or halogen.
2. The compound of claim 1 , wherein Y═Z is
(a) CH═O, CH 2 —I, CH 2 —Br, CH 2 —Cl, CH 2 —OPO(OH) 2 , CH 2 -OTs, CO—NHS or CH═CH 2 , wherein OTs is p-toluene sulfonyloxy and NHS is N-oxy-succinimide; or
(b) O—I, O—Br, O—Cl, S—I, S—Br or S—I.
3. The compound of claim 1 , wherein R 2 and R 3 are identical.
4. The compound of claim 1 , wherein X is C═O and Y═Z is CH═O or CO—NHS.
5. A method of inhibiting a proteasome, said method comprising bringing into contact a proteasome and a compound as defined in claim 1 .
6. A method of treating, ameliorating or preventing cancer, an autoimmune disease, muscular dystrophy, emphysema, or cachexia accompanying cancer or AIDS, comprising administering a compound as defined in claim 1 to a subject in need thereof.
7. The method of claim 6 , wherein
(a) said cancer is a lymphoid malignancy, wherein the lymphoid malignancy is multiple myeloma (MM) or non-Hodgkin lymphoma, wherein the non-Hodgkin lymphoma is a B-cell lymphoma selected from mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and Waldenström macroglobulinaemia; or
(b) said autoimmune disease is rheumatoid arthritis, systemic lupus erythematosus, Sjörgen's syndrome or scleroderma.
8. The compound of claim 3 , wherein R 2 and R 3 are selected from methyl, methoxy, and —CH 2 OH.